IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9890112 B1

PDFFull Text
Date of Patent:
Feb. 13, 2018

Filed:

Apr. 02, 2012

Compounds for use as therapeutic agents affecting p53 expression and/or activity

Applicants:

Didier Scherrer, Castelnau le Lez, FR;

Jamal Tazi, Clapiers, FR;

Romain Najman, L'Hay-les-Roses, FR;

Florence Mahuteau, Saint Remy les Chevreuses, FR;

Pierre Roux, Saint-Gely-du-Fesc, FR;

Inventors:

Didier Scherrer, Castelnau le Lez, FR;

Jamal Tazi, Clapiers, FR;

Romain Najman, L'Hay-les-Roses, FR;

Florence Mahuteau, Saint Remy les Chevreuses, FR;

Pierre Roux, Saint-Gely-du-Fesc, FR;

Assignees:

ABIVAX, Paris, FR;

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris, FR;

INSTITUT CURIE, Paris, FR;

UNIVERSITE DE MONTPELLIER, Montpellier, FR;

Attorney:

Oliff PLC

Primary Examiner:

Daniel R Carcanague

Int. Cl.
CPC ...
C07D 401/12 (2006.01); C07C 237/30 (2006.01); C07D 213/38 (2006.01); C07D 233/61 (2006.01); A61K 31/166 (2006.01); A61K 31/167 (2006.01); A61K 31/4164 (2006.01); A61K 31/417 (2006.01); A61K 31/4192 (2006.01); A61K 31/4409 (2006.01); A61K 31/4439 (2006.01); A61K 31/4545 (2006.01); A61K 31/495 (2006.01); A61K 31/496 (2006.01); A61K 31/5377 (2006.01); C07D 213/36 (2006.01); C07D 233/64 (2006.01); C07D 249/06 (2006.01);
U.S. Cl.
CPC ...
C07C 237/30 (2013.01); A61K 31/166 (2013.01); A61K 31/167 (2013.01); A61K 31/417 (2013.01); A61K 31/4164 (2013.01); A61K 31/4192 (2013.01); A61K 31/4409 (2013.01); A61K 31/4439 (2013.01); A61K 31/4545 (2013.01); A61K 31/495 (2013.01); A61K 31/496 (2013.01); A61K 31/5377 (2013.01); C07D 213/36 (2013.01); C07D 213/38 (2013.01); C07D 233/61 (2013.01); C07D 233/64 (2013.01); C07D 249/06 (2013.01); C07D 401/12 (2013.01);
Abstract

The present invention relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C-C)alkoxy group, a fluoro(C-C)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C-C)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a —NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C-C)alkyl group, a CONHR6 group, a —CONR7R8 group, a —SONHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a —(CH)NR7R8 group or a hydroxy(C-C)alkyl group; R6 represents a hydrogen atom, a —(CHR9)(CH)NR7R8 group or a (C-C)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the invention.

Find Patent Forward Citations

Loading…